Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 10/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17767124 | 0.84 | PDE2A (0.42) | ALDH1A1PDE2APDE3APDE10A | |
| SCHEMBL17767126 | 0.84 | PDE2A (0.42) | ALDH1A1PDE2APDE3APDE10A | |
| SCHEMBL2862463 | 0.83 | EEF2K (0.37) | PDE2AL3MBTL1 | |
| SCHEMBL25189956 | 0.83 | SMN1; SMN2 (0.34) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL30360115 | 0.83 | SMN1; SMN2 (0.34) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL25264994 | 0.83 | SMN1; SMN2 (0.34) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL25264993 | 0.83 | SMN1; SMN2 (0.34) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL13216631 | 0.82 | PDE2A (0.41) | ALDH1A1PDE2AL3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL19578925 | 0.81 | SMN1; SMN2 (0.35) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL31316767 | 0.81 | SMN1; SMN2 (0.35) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216761-A1 | NOVEL AZETIDINONES USEFUL AS INHIBITORS OF ELASTASE | MERCK SHARP & DOHME CORP. | 2010-08-26 | — | — | US | disclosed |
| EP-2209372-A1 | NOVEL AZETIDINONES USEFUL AS INHIBITORS OF ELASTASE | Merck Sharp & Dohme Corp. (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009045419-A1 | NOVEL AZETIDINONES USEFUL AS INHIBITORS OF ELASTASE | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216761-A1 | NOVEL AZETIDINONES USEFUL AS INHIBITORS OF ELASTASE | ELANE, SERPINB1, MMP8 | ALDH1A1 1715/4885CYP1A2 1926/4885CYP3A4 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.